Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma

Published:2018-08-23 Issue:8 Volume:132 Page:777-781
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chow Victor A.¹²³^ORCID,Shadman Mazyar¹²³^ORCID,Gopal Ajay K.¹²³^ORCID

Affiliation:

1. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA;

2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and

3. Seattle Cancer Care Alliance, Seattle, WA

Abstract

Abstract Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) for large B-cell lymphomas after 2 prior lines of therapy. Durable remissions are seen in 30% to 40% of study-treated patients, but toxicities of cytokine release syndrome and neurotoxicity require administration in specialized centers. This article reviews data of current diffuse large B-cell lymphoma management, focusing on axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/8/777/1466975/blood839217.pdf

Reference29 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes;Teras;CA Cancer J Clin,2016

2. Relapsed/refractory diffuse large B-cell lymphoma;Friedberg,2011

3. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study;Van Den Neste;Bone Marrow Transplant,2017

4. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

5. Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients;Fenske;Biol Blood Marrow Transplant,2016

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma;Human Vaccines & Immunotherapeutics;2024-02

2. A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma;Frontiers in Oncology;2024-02-01

3. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis;Transplantation and Cellular Therapy;2024-01

4. Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients;BMC Cancer;2023-10-23

5. A novel mesenchymal stem cell-based regimen for acute myeloid leukemia differentiation therapy;Acta Pharmaceutica Sinica B;2023-07